In vitro characterization of botulinum toxin types A, C and D action on human tissues: Combined electrophysiologic, pharmacologic and molecular biologic approaches

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 3, 1997, Pages 1489-1498

  Coffield, J A ^a   Bakry, N ^a   Zhang, R D ^a   Carlson, J ^a   Gomella, L G ^a   Simpson, L L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN C; BOTULINUM TOXIN D; POLYPEPTIDE; SYNTAXIN; UNCLASSIFIED DRUG;

ARTICLE; BOTULISM; BRAIN TISSUE; CONTROLLED STUDY; DYSTONIA; HUMAN; HUMAN TISSUE; LIGAND BINDING; MINIATURE ENDPLATE POTENTIAL; NERVE FIBER MEMBRANE STEADY POTENTIAL; NEUROMUSCULAR TRANSMISSION; PRIORITY JOURNAL; SKELETAL MUSCLE;

BOTULINUM TOXINS; CELL MEMBRANE; HUMANS; MOTOR ENDPLATE; MUSCLE, SKELETAL; NEUROMUSCULAR JUNCTION;

EID: 0030897432     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. AMERICAN ACADEMY OF NEUROLOGY: Assessment. The clinical usefulness of botulinum toxin-A in treating neurological disorders. Neurology 40: 1332-1336, 1990.
2. BAKRY, N., KAMATA, Y., SORENSEN, R. AND SIMPSON, L. L.: Tetanus toxin and neuronal membranes: The relationship between binding and toxicity. J. Pharmacol. Exp. Ther. 258: 613-619, 1991.
3. BARK, I. C. AND WILSON, M. C.: Human cDNA clones encoding two different isoforms of the nerve terminal protein SNAP-25. Gene 139: 291-292, 1994.
4. BEATON, L. E. AND ANSON, B. J.: Pyramidalis muscle: Its occurrence and size in American whites and Negroes. Am. J. Phys. Anthrop. 25: 261-269, 1939.
5. BINZ, T., BLASI, J., YAMASAKI, S., BAUMEISTER, A., LINK, E., SÜDHOF, T. C., JAHN, R. AND NIEMANN, H.: Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J. Biol. Chem. 269: 1617-1620, 1994.
6. BLASI, J., CHAPMAN, E. R., LINK, E., BINZ, T., YAMASAKI, S., DE CAMILLI, P., SÜDHOF, T. C., NIEMANN, H. AND JAHN, R.: Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature (Lond.) 365: 160-163, 1993a.
7. BLASI, J., CHAPMAN, E. R., YAMASAKI, S., BINZ, T., NIEMANN, H.20AND JAHN, R.: Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J. 12: 4821-4828, 1993b.
8. BOUCHER, P., SATO, H., SATO, Y. AND LOCHT, C.: Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. Infect. Immun. 62: 449-456, 1994.
9. CHATFIELD, S. N., CHARLES, I. G. AND MAKOFF, A. J.: Use of the nirB promotor to direct the stable expression of heterologous antigens in salmonella oral vaccine strains: Development of a single dose oral tetanus vaccine. Bio/Technology 10: 888-892, 1992.
10. CHOUKE, K. S.: The constitution of the sheath of the rectus abdominus muscle. Anat. Rec. 61: 341-349, 1935.
11. DOWELL, V. R., JR.: Botulism and tetanus: Selected epidemiologic and microbiologic aspects. Rev. Infect. Dis. 6: suppl. 1, S202-S207, 1984.
12. ELMQVIST, D.20AND QUASTEL, D. M.: A quantitative study of end-plate potentials in isolated human muscle. J. Physiol., (Lond.) 178: 505-529, 1965.
13. FAIRWEATHER, N. F., LYNESS, V. A. AND MASKELL, D. J.: Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect. Immun. 55: 2541-2545, 1987.
14. FORAN, P., LAWRENCE, G. W., SHONE, C. C., FOSTER, K. A. AND DOLLY, J. O.: Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: Correlation with its blockade of catecholamine release. Biochemistry 35: 2630-2636, 1996.
15. GANGAROSA, E. J., DONADIO, J. A., ARMSTRONG, R. W., MEYER, K. F., BRACHMAN, P. S. AND DOWELL, V. R.: Botulism in the United States. 1899-1969. Am. J. Epidemiol. 93: 93-101, 1971.
16. HABERMANN, E. AND DREVER, F.: Clostridial neurotoxins: Handling and action at the cellular level. Curr. Topics Microbiol. Immunol. 129: 93-179, 1986.
17. HAYNES, J.: Miniature end-plate potentials in neuromuscular disease: An electrophysiological investigation of motor-point muscle biopsies. J. Neurol. Neurosurg. Psychiat. 34: 521-526, 1971.
18. JANKOVIC, J. AND BRIN, M. F.: Therapeutic uses of botulinum toxin. N. Engl. J. Med. 324: 1186-1194, 1991.
19. JANKOVIC, J. AND HALLETT, M.: Therapy with Botulinum Toxin, Marcell Dekker, Inc. New York, 1994.
20. LAMBERT, E. H. AND ELMQVIST, D.: Quantal components of end-plate potentials in the myasthenic syndrome. Ann N. Y. Acad. Sci. 183: 183-199, 1971.
21. MASELLI, R. A., BURNETT, M. E. AND TONSGARD, J. H.: In vitro microelectrode study of neuromuscular transmission in a case of botulism. Muscle Nerve 15: 273-276, 1992.
22. MASELLI, R. A., MASS, D. P., DISTAD, B. J. AND RICHMAN, D. P.: Anconeus muscle: A human muscle preparation suitable for in vitro microelectrode studies. Muscle Nerve 14: 1189-1192, 1991.
23. MONKHOUSE, W. S. AND KHALIQUE, A.: Variations in the composition of the human rectus sheath: A study of the anterior abdominal wall. J. Anat. 145: 61-66, 1986.
24. NIH CONSENSUS STATEMENT: Clinical use of botulinum toxin. Arch. Neurol. 48: 1294-1298, 1991.
25. OGUMA, K., YOKOTA, K., HAYASHI, S., TAKESHI, K., KUMAGAI, M., ITOH, N., TACHI, N. AND CHIBA, S.: Infant botulism due to Clostridium botulinum type C toxin [letter]. Lancet 336: 1449-1450, 1990.
26. PEVSNER, J., HSU, S. C., BRAUN, J. E. A., CALAKOS, N., TING, A. E., BENNETT, M. K. AND SCHELLER, R. H.: Specificity and regulation of a synaptic vesicle docking complex. Neuron 13: 353-361, 1994.
27. POULAIN, B., MOCHIDA, S., WELLER, U., HÖGY, B., HABERMANN, E., WADSWORTH, J. D. F., SHONE, C. C., DOLLY, J. O. AND TAUC, L.: Heterologous combinations of heavy and light chains from botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in Aplysia. J. Biol. Chem. 266: 9580-9585, 1991.
28. POULAIN, B., WADSWORTH, J. D. F., SHONE, C. C., MOCHIDA, S., LANDE, S., MELLING, J., DOLLY, J. O. AND TAUC, L.: Multiple domains of botulinum neurotoxin contribute to its inhibition of transmitter release in Aplysia neurons. J. Biol. Chem. 264: 21928-21933, 1989.
29. SANGER, F., NICKLEN, S. AND COULSON, A. R.: DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74: 5463-5467, 1977.
30. SCHIAVO, G., BENFENATI, F., POULAIN, B., ROSSETTO, O., POLVERINO DE LAURETO, P., DASGUPTA, B. R. AND MONTECUCCO, C.: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature (Lond.) 359: 832-835, 1992.
31. SCHIAVO, G., MALIZIO, C., TRIMBLE, W. S., POLVERINO DE LAURETO, P., SUGIYAMA, H., JOHNSON, E. A. AND MONTECUCCO, C.: Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J. Biol. Chem. 269: 20213-20216, 1994a.
32. SCHIAVO, G., ROSSETTO, O., CATSICAS, S., DE LAURETO, P. P., DASGUPTA, B. R., BENFENATI, F. AND MONTECUCCO, C.: Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D and E. J. Biol. Chem. 268: 23784-23787, 1993a.
33. SCHIAVO, G., ROSSETTO, O. AND MONTECUCCO, C.: Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release. Sem. Cell Biol. 5: 221-229, 1994b.
34. SCHIAVO, G., SHONE, C. C., ROSSETTO, O., ALEXANDER, F. C. G. AND MONTECUCCO, C.: Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J. Biol. Chem. 268: 11516-11519, 1993b.
35. SIMPSON, L. L.: Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J. Pharmacol. Exp. Ther. 212: 16-21, 1980.
36. SIMPSON, L. L.: The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 33: 155-188, 1981.
37. SIMPSON, L. L.: Botulinum Neurotoxin and Tetanus Toxin, Academic Press. San Diego, 1989.
38. SIMPSON, L. L., SCHMIDT, J. J. AND MIDDLEBROOK, J. L.: Isolation and characterization of the botulinum neurotoxins. Meth. Enzymol. 165: 76-85, 1988.
39. SLATER, C. R., LYONS, P. R., WALLS, T. J., FAQCETI, P. R. W. AND YOUNG, C.: Structure and function of neuromuscular junctions in the vastus lateralis of man. Brain 115: 451-478, 1992.
40. SÖLLNER, T., BENNETT, M. K., WHITEHEAD, S. W., SCHELLER, R. H. AND ROTHMAN, J.: A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 75: 409-418, 1993a.
41. SÖLLNER, T., WHITEHEART, S. W., BRUNNER, M., ERDJUMENT-BROMAGE, H., GERMANOS, S., TEMPST, P. AND ROTHMAN, J.: SNAP receptors implicated in vesicle targeting and fusion. Nature (Lond.) 362: 318-324, 1993b.
42. SÜDHOF, T. C., DE CAMILLI, P., NIEMANN, H. AND JAHN, R.: Membrane fusion machinery: Insights from synaptic proteins. Cell 75: 1-4, 1993.
43. WILLIAMSON, L. C., HALPERN, J. L., MONTECUCCO, C., BROWN, J. E. AND NEALE, E. A.: Clostridial neurotoxins and substrate proteolysis in intact neurons. J. Biol. Chem. 271: 7694-7699, 1996.
44. YAMASAKI, S., BAUMEISTER, A., BINZ, T., BLASI, J., LINK, E., CORNILLE, F., ROQUES, B., FYKSE, E. M., SÜDHOF, T. C., JAHN, R. AND NIEMANN, H.: Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem. 269: 12764-12772, 1994a.
45. YAMASAKI, S., BINZ, T., HAYASHI, T., SZABO, E., YAMASAKI, N., EKLUND, M., JAHN, R. AND NIEMANN, H.: Botulinum neurotoxin type G proteolyses the Ala81-Ala82 bond of rat synaptobrevin 2. Biochem. and Biophys. Res. Comm. 220: 829-835, 1994b.
46. ZHANG, R., MAKSYMOWYCH, A. B. AND SIMPSON, L. L.: Cloning and sequence analysis of a cDNA encoding human syntaxin 1A, a polypeptide essential for exocytosis. Gene 159: 293-294, 1995.